These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 28594478)

  • 21. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
    Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
    S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of economics and cost-effectiveness analyses of anticoagulant therapy for stroke prevention in atrial fibrillation in the US.
    von Schéele B; Fernandez M; Hogue SL; Kwong WJ
    Ann Pharmacother; 2013 May; 47(5):671-85. PubMed ID: 23606551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
    Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.
    Hesselbjerg LJ; Pedersen HS; Asmussen MB; Petersen KD
    J Med Econ; 2013 Jul; 16(7):845-58. PubMed ID: 23621506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark.
    Langkilde LK; Bergholdt Asmussen M; Overgaard M
    J Med Econ; 2012; 15(4):695-703. PubMed ID: 22397590
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Cost-effectiveness of apixaban compared to other new oral anticoagulants in patients with non-valvular atrial fibrillation].
    Rudakova AV; Tatarskiĭ BA
    Kardiologiia; 2014; 54(7):43-52. PubMed ID: 25177813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.
    You JH; Tsui KK; Wong RS; Cheng G
    PLoS One; 2012; 7(6):e39640. PubMed ID: 22745801
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses.
    Pink J; Lane S; Pirmohamed M; Hughes DA
    BMJ; 2011 Oct; 343():d6333. PubMed ID: 22042753
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic evaluation of percutaneous left atrial appendage occlusion, dabigatran, and warfarin for stroke prevention in patients with nonvalvular atrial fibrillation.
    Singh SM; Micieli A; Wijeysundera HC
    Circulation; 2013 Jun; 127(24):2414-23. PubMed ID: 23697908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness modelling of novel oral anticoagulants incorporating real-world elderly patients with atrial fibrillation.
    Zhao YJ; Lin L; Zhou HJ; Tan KT; Chew AP; Foo CG; Oh CT; Lim BP; Lim WS
    Int J Cardiol; 2016 Oct; 220():794-801. PubMed ID: 27400183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.
    Li X; Tse VC; Lau WC; Cheung BM; Lip GY; Wong IC; Chan EW
    PLoS One; 2016; 11(6):e0157129. PubMed ID: 27362421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation.
    Lanitis T; Kongnakorn T; Jacobson L; De Geer A
    Thromb Res; 2014 Aug; 134(2):278-87. PubMed ID: 24935675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation.
    Kamel H; Easton JD; Johnston SC; Kim AS
    Neurology; 2012 Oct; 79(14):1428-34. PubMed ID: 22993279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium.
    Wouters H; Thijs V; Annemans L
    J Med Econ; 2013; 16(3):407-14. PubMed ID: 23320796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for atrial fibrillation in Portugal.
    Costa J; Fiorentino F; Caldeira D; Inês M; Lopes Pereira C; Pinheiro L; Vaz-Carneiro A; Borges M; Gouveia M
    Rev Port Cardiol; 2015 Dec; 34(12):723-37. PubMed ID: 26616542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Is dabigatran cost effective compared with warfarin for stroke prevention in atrial fibrillation? A critically appraised topic.
    Adcock AK; Lee-Iannotti JK; Aguilar MI; Hoffman-Snyder CR; Wingerchuk DM; Wellik KE; Demaerschalk BM
    Neurologist; 2012 Mar; 18(2):102-7. PubMed ID: 22367842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation.
    Kansal AR; Zheng Y; Pokora T; Sorensen SV
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):225-37. PubMed ID: 23953910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation.
    Shah SV; Gage BF
    Circulation; 2011 Jun; 123(22):2562-70. PubMed ID: 21606397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.